Natco Pharma Limited

Natco Pharma Limited (NATCOPHARM) is a small-cap Healthcare company valued at ₹15,404 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Natco Pharma Limited last traded at ₹785.2, modestly up 0.33% on the day.

Recent developments

On 2026-09-28, Natco Pharma increased its investment in US biotech eGenesis to $16.7 million, supporting gene-edited organ research. On 2026-09-25, the company approved a rights issue to raise up to ₹1,279.35 crore. On 2026-09-01, the CEO discussed the company's strategy to move beyond generics for future growth. On 2026-08-16, Natco Pharma published its Q1 FY27 results and announced an interim dividend.

Financial performance

Natco Pharma's annual revenue fell 7.9% to ₹4,078 crore, while annual net profit dropped 24.7% to ₹1,418 crore. The latest quarter saw revenue and net profit both decline significantly, with revenue down 44.7% and net profit down 57.0% compared to the same quarter a year earlier. The net profit margin narrowed 7.7 percentage points to 34.8%, despite a return on equity and return on capital employed remaining stable at 15.4% and 15.8%, respectively.

Valuation multiples

The stock trades at 9.9 times earnings, a discount to the Healthcare median of 32.0, 1.59 times book value. It yields 0.2%.

Things to watch

The stock is 33.1% below its 52-week high, and the latest quarter's net profit fell 57.0% compared to the same quarter a year earlier. The net profit margin narrowed 7.7 percentage points to 34.8%, indicating pressure on profitability. The company's annual net profit declined 24.7% despite a 14.6% revenue CAGR over the past three years.

Where it stands

Natco Pharma's business has slowed, with annual revenue and net profit both declining, and the latest quarter showing sharp drops in both metrics. The stock is significantly below its 52-week high, and the net profit margin has narrowed. The most significant movement is the 57.0% drop in net profit for the latest quarter compared to the same period a year earlier.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.